Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)vsTeva Pharma Industries Ltd ADR (TEVA)
AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
$12.26
+1.57%
HEALTHCARE · Cap: $3.80B
TEVA
Teva Pharma Industries Ltd ADR
$29.46
+1.10%
HEALTHCARE · Cap: $33.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 472% more annual revenue ($17.26B vs $3.02B). TEVA leads profitability with a 8.2% profit margin vs 2.4%. TEVA trades at a lower P/E of 24.1x. TEVA earns a higher WallStSmart Score of 73/100 (B).
AMRX
Hold46
out of 100
Grade: D+
TEVA
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-42.7%
Fair Value
$10.30
Current Price
$12.26
$1.96 premium
Margin of Safety
+39.4%
Fair Value
$56.63
Current Price
$29.46
$27.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.3%
Earnings expanding 40.0% YoY
Generating 1.0B in free cash flow
Areas to Watch
2.6% earnings growth
2.4% margin — thin
Premium valuation, high expectations priced in
ROE of -8.8% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AMRX
Revenue growth of 11.5% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.43 suggests the stock is reasonably priced for its growth.
Bear Case : AMRX
The primary concerns for AMRX are EPS Growth, Profit Margin, P/E Ratio. A P/E of 54.9x leaves little room for execution misses. Thin 2.4% margins leave little buffer for downturns.
Bear Case : TEVA
The primary concerns for TEVA are Altman Z-Score.
Key Dynamics to Monitor
AMRX carries more volatility with a beta of 1.30 — expect wider price swings.
AMRX is growing revenue faster at 11.5% — sustainability is the question.
TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TEVA scores higher overall (73/100 vs 46/100) and 11.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amneal Pharmaceuticals, Inc. Class A Common Stock
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?